February 5, 2025 01:57 PM EST

Small personalized vaccine trial sees progress in late-stage kidney cancer

Zachary Brennan

Senior Editor

All nine late-stage kidney cancer patients in a Phase 1 trial of a personalized vaccine remained cancer-free after about three years of receiving treatment, researchers …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Small personalized vaccine trial sees progress in late-stage kidney cancer

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bristol Myers, Kyowa Kirin disclose layoffs

Amgen announces hold on Phase 1 obesity candidate, pipeline cuts

EyePoint shares more mid-stage data for therapy trying to compete with Regeneron's Eylea

Pfizer says it has at least $10B available for deals in 2025, with a focus on pipeline

Novo Nordisk is feeling the competition from compounded GLP-1s, exec says

GSK defiant against vaccine challenges, will prioritize other growth areas

Small per­son­al­ized vac­cine tri­al sees progress in late-stage kid­ney can­cer

Senior Editor

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Small personalized vaccine trial sees progress in late-stage kidney cancer